Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Graft vs Host Disease | 30 | 2022 | 2818 | 2.910 |
Why?
|
Hematopoietic Stem Cell Transplantation | 33 | 2022 | 5135 | 2.410 |
Why?
|
Bone Marrow Transplantation | 21 | 2017 | 2789 | 2.350 |
Why?
|
Anemia, Sickle Cell | 15 | 2022 | 966 | 1.780 |
Why?
|
Transplantation Conditioning | 17 | 2022 | 1553 | 1.590 |
Why?
|
HLA Antigens | 11 | 2019 | 1549 | 1.050 |
Why?
|
Leukemia, Myeloid, Acute | 13 | 2022 | 3281 | 1.050 |
Why?
|
Hematologic Diseases | 4 | 2017 | 489 | 0.980 |
Why?
|
Leukemia | 6 | 2017 | 1496 | 0.820 |
Why?
|
Erythrocyte Transfusion | 4 | 2016 | 519 | 0.810 |
Why?
|
Histocompatibility | 4 | 2013 | 362 | 0.760 |
Why?
|
Vidarabine | 2 | 2015 | 348 | 0.750 |
Why?
|
Isoantibodies | 5 | 2019 | 660 | 0.740 |
Why?
|
Histocompatibility Testing | 9 | 2019 | 804 | 0.720 |
Why?
|
Siblings | 8 | 2017 | 806 | 0.710 |
Why?
|
Busulfan | 3 | 2015 | 271 | 0.620 |
Why?
|
Cord Blood Stem Cell Transplantation | 3 | 2015 | 338 | 0.610 |
Why?
|
Virus Activation | 2 | 2015 | 326 | 0.580 |
Why?
|
H-Y Antigen | 1 | 2015 | 43 | 0.570 |
Why?
|
Cytomegalovirus Infections | 3 | 2016 | 753 | 0.560 |
Why?
|
Antilymphocyte Serum | 3 | 2015 | 520 | 0.550 |
Why?
|
Anemia, Aplastic | 3 | 2015 | 236 | 0.550 |
Why?
|
Leukemia, Biphenotypic, Acute | 3 | 2019 | 32 | 0.540 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2015 | 1418 | 0.520 |
Why?
|
Transplantation, Homologous | 19 | 2022 | 4831 | 0.510 |
Why?
|
Cytomegalovirus | 2 | 2015 | 681 | 0.500 |
Why?
|
Rifamycins | 1 | 2013 | 26 | 0.500 |
Why?
|
Tissue Donors | 6 | 2021 | 2147 | 0.490 |
Why?
|
Viremia | 1 | 2016 | 728 | 0.490 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 4 | 2012 | 277 | 0.480 |
Why?
|
Lymphocyte Depletion | 1 | 2015 | 638 | 0.480 |
Why?
|
Graft Rejection | 7 | 2014 | 4408 | 0.470 |
Why?
|
Cyclophosphamide | 3 | 2015 | 2189 | 0.420 |
Why?
|
Acute Disease | 11 | 2021 | 7158 | 0.390 |
Why?
|
Child | 44 | 2022 | 73636 | 0.390 |
Why?
|
Adolescent | 43 | 2021 | 84718 | 0.380 |
Why?
|
Bacteremia | 1 | 2016 | 968 | 0.380 |
Why?
|
Child, Preschool | 32 | 2019 | 41081 | 0.360 |
Why?
|
Immunophenotyping | 5 | 2019 | 1908 | 0.360 |
Why?
|
Infant | 23 | 2019 | 34261 | 0.320 |
Why?
|
Recombinant Fusion Proteins | 1 | 2015 | 3878 | 0.300 |
Why?
|
Cross-Priming | 1 | 2005 | 77 | 0.280 |
Why?
|
Young Adult | 24 | 2021 | 55940 | 0.270 |
Why?
|
Thalassemia | 1 | 2005 | 267 | 0.260 |
Why?
|
Immunity | 1 | 2010 | 957 | 0.260 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2005 | 322 | 0.260 |
Why?
|
Diagnostic Tests, Routine | 1 | 2010 | 791 | 0.260 |
Why?
|
Decision Making | 1 | 2018 | 3802 | 0.250 |
Why?
|
Living Donors | 5 | 2014 | 569 | 0.240 |
Why?
|
Myeloablative Agonists | 5 | 2014 | 224 | 0.230 |
Why?
|
Immunity, Innate | 1 | 2015 | 2937 | 0.230 |
Why?
|
African Americans | 3 | 2016 | 5118 | 0.230 |
Why?
|
Glomerular Filtration Rate | 1 | 2010 | 2090 | 0.230 |
Why?
|
Immunosuppressive Agents | 7 | 2021 | 4226 | 0.220 |
Why?
|
Myelodysplastic Syndromes | 3 | 2022 | 1255 | 0.220 |
Why?
|
Graft Survival | 8 | 2015 | 3767 | 0.210 |
Why?
|
Disease-Free Survival | 12 | 2019 | 7026 | 0.210 |
Why?
|
Cause of Death | 2 | 2013 | 3497 | 0.210 |
Why?
|
Immunization | 1 | 2005 | 1273 | 0.200 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7487 | 0.200 |
Why?
|
Humans | 66 | 2022 | 708843 | 0.190 |
Why?
|
Male | 45 | 2021 | 349524 | 0.190 |
Why?
|
Female | 47 | 2021 | 375205 | 0.190 |
Why?
|
Antibodies | 2 | 2018 | 2431 | 0.180 |
Why?
|
Remission Induction | 7 | 2014 | 2399 | 0.180 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2014 | 1454 | 0.170 |
Why?
|
Hemostatics | 1 | 2001 | 224 | 0.170 |
Why?
|
Whole-Body Irradiation | 5 | 2014 | 459 | 0.170 |
Why?
|
T-Lymphocytes | 2 | 2013 | 10362 | 0.170 |
Why?
|
Thrombophilia | 1 | 2001 | 318 | 0.170 |
Why?
|
Hematologic Neoplasms | 2 | 2013 | 1687 | 0.170 |
Why?
|
Adult | 31 | 2021 | 211041 | 0.160 |
Why?
|
Survival Analysis | 9 | 2017 | 10507 | 0.160 |
Why?
|
Neutropenia | 2 | 2016 | 871 | 0.160 |
Why?
|
Immunoconjugates | 2 | 2014 | 831 | 0.160 |
Why?
|
Antisickling Agents | 2 | 2015 | 78 | 0.160 |
Why?
|
Platelet Transfusion | 1 | 2019 | 285 | 0.160 |
Why?
|
Infant, Newborn | 9 | 2018 | 24433 | 0.150 |
Why?
|
Risk Factors | 13 | 2018 | 69553 | 0.150 |
Why?
|
Hindlimb | 1 | 2018 | 551 | 0.150 |
Why?
|
Down Syndrome | 2 | 2014 | 792 | 0.150 |
Why?
|
Erythrocytes | 1 | 2005 | 2418 | 0.150 |
Why?
|
Hydroxyurea | 2 | 2015 | 290 | 0.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 11253 | 0.140 |
Why?
|
Platelet Membrane Glycoproteins | 1 | 2016 | 293 | 0.140 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 200 | 0.140 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2021 | 4254 | 0.140 |
Why?
|
Age Factors | 7 | 2017 | 18712 | 0.140 |
Why?
|
Seasons | 1 | 2001 | 1433 | 0.140 |
Why?
|
Dyskeratosis Congenita | 1 | 2015 | 74 | 0.140 |
Why?
|
Blood Component Transfusion | 1 | 2015 | 126 | 0.130 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2010 | 679 | 0.130 |
Why?
|
Peroxidase | 1 | 2017 | 636 | 0.130 |
Why?
|
Donor Selection | 2 | 2013 | 188 | 0.130 |
Why?
|
Follow-Up Studies | 12 | 2021 | 39038 | 0.130 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2018 | 474 | 0.120 |
Why?
|
Respiratory Tract Infections | 1 | 2001 | 961 | 0.120 |
Why?
|
Inflammation | 1 | 2013 | 10019 | 0.120 |
Why?
|
Blood Donors | 2 | 2012 | 355 | 0.120 |
Why?
|
Fanconi Anemia | 1 | 2015 | 326 | 0.120 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 255 | 0.110 |
Why?
|
Lymphocyte Activation | 3 | 2013 | 5908 | 0.110 |
Why?
|
Prognosis | 7 | 2021 | 28919 | 0.110 |
Why?
|
Receptors, Interleukin-2 | 1 | 2013 | 605 | 0.110 |
Why?
|
Retrospective Studies | 13 | 2022 | 71483 | 0.110 |
Why?
|
Genetic Diseases, Inborn | 1 | 2016 | 598 | 0.110 |
Why?
|
Leukocyte-Adhesion Deficiency Syndrome | 1 | 2010 | 21 | 0.100 |
Why?
|
Immunocompromised Host | 1 | 2016 | 882 | 0.100 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 821 | 0.100 |
Why?
|
Diabetes Complications | 1 | 2018 | 1394 | 0.100 |
Why?
|
Immunity, Mucosal | 1 | 2014 | 485 | 0.100 |
Why?
|
Neovascularization, Physiologic | 1 | 2018 | 1422 | 0.100 |
Why?
|
Gonadal Disorders | 1 | 2009 | 6 | 0.100 |
Why?
|
Recurrence | 5 | 2022 | 8255 | 0.090 |
Why?
|
Disease Susceptibility | 1 | 2016 | 1778 | 0.090 |
Why?
|
Spleen | 1 | 2016 | 2473 | 0.090 |
Why?
|
Disease Management | 2 | 2018 | 2536 | 0.090 |
Why?
|
Ischemia | 1 | 2018 | 1934 | 0.090 |
Why?
|
Treatment Outcome | 14 | 2014 | 61932 | 0.090 |
Why?
|
C-Reactive Protein | 1 | 2001 | 3696 | 0.090 |
Why?
|
Blood Transfusion | 1 | 2015 | 1246 | 0.090 |
Why?
|
Survival Rate | 7 | 2013 | 13202 | 0.090 |
Why?
|
beta-Thalassemia | 1 | 2010 | 234 | 0.090 |
Why?
|
Lung Diseases, Obstructive | 1 | 2009 | 315 | 0.090 |
Why?
|
Immunologic Memory | 1 | 2015 | 1391 | 0.080 |
Why?
|
Referral and Consultation | 1 | 2021 | 3436 | 0.080 |
Why?
|
Odds Ratio | 2 | 2015 | 9754 | 0.080 |
Why?
|
Antineoplastic Agents | 3 | 2013 | 13714 | 0.080 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2007 | 637 | 0.080 |
Why?
|
Proportional Hazards Models | 3 | 2013 | 12292 | 0.080 |
Why?
|
Etoposide | 2 | 2006 | 631 | 0.080 |
Why?
|
Sirolimus | 2 | 2014 | 1571 | 0.080 |
Why?
|
Chromosome Aberrations | 1 | 2013 | 1814 | 0.080 |
Why?
|
T-Lymphocyte Subsets | 1 | 2015 | 1924 | 0.080 |
Why?
|
Leukocytes | 1 | 2015 | 2095 | 0.080 |
Why?
|
Transplantation Chimera | 2 | 2009 | 623 | 0.070 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2007 | 222 | 0.070 |
Why?
|
Leukocyte Reduction Procedures | 1 | 2005 | 17 | 0.070 |
Why?
|
Anti-Infective Agents | 1 | 2013 | 927 | 0.070 |
Why?
|
Colony-Stimulating Factors | 1 | 2006 | 221 | 0.070 |
Why?
|
Killer Cells, Natural | 1 | 2015 | 2165 | 0.070 |
Why?
|
Chronic Disease | 2 | 2017 | 8992 | 0.070 |
Why?
|
Recovery of Function | 1 | 2016 | 2950 | 0.070 |
Why?
|
Central Nervous System Diseases | 1 | 2009 | 532 | 0.070 |
Why?
|
Growth | 1 | 2007 | 393 | 0.070 |
Why?
|
Creatinine | 1 | 2010 | 1885 | 0.070 |
Why?
|
Adrenal Cortex Hormones | 1 | 2014 | 1851 | 0.070 |
Why?
|
Cyclosporine | 2 | 2021 | 826 | 0.070 |
Why?
|
Multivariate Analysis | 3 | 2011 | 12447 | 0.070 |
Why?
|
Hemoglobinopathies | 1 | 2005 | 101 | 0.070 |
Why?
|
Pancytopenia | 1 | 2005 | 106 | 0.060 |
Why?
|
Pilot Projects | 2 | 2015 | 7994 | 0.060 |
Why?
|
Tacrolimus | 2 | 2021 | 717 | 0.060 |
Why?
|
Ovalbumin | 1 | 2005 | 729 | 0.060 |
Why?
|
Chickens | 1 | 2005 | 875 | 0.060 |
Why?
|
Reference Values | 1 | 2011 | 5041 | 0.060 |
Why?
|
Case-Control Studies | 3 | 2017 | 21194 | 0.060 |
Why?
|
Interleukin-6 | 1 | 2013 | 3179 | 0.060 |
Why?
|
Combined Modality Therapy | 4 | 2014 | 8896 | 0.060 |
Why?
|
Middle Aged | 14 | 2021 | 213752 | 0.060 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2010 | 1756 | 0.060 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2006 | 630 | 0.060 |
Why?
|
Analysis of Variance | 1 | 2011 | 6530 | 0.050 |
Why?
|
Forecasting | 1 | 2011 | 2941 | 0.050 |
Why?
|
Antigens, CD34 | 1 | 2003 | 673 | 0.050 |
Why?
|
Kidney Failure, Chronic | 1 | 2014 | 2559 | 0.050 |
Why?
|
Transplantation, Autologous | 2 | 2018 | 2092 | 0.050 |
Why?
|
Cross-Sectional Studies | 3 | 2016 | 23020 | 0.050 |
Why?
|
Matched-Pair Analysis | 1 | 2001 | 281 | 0.050 |
Why?
|
Macaca mulatta | 2 | 2021 | 2427 | 0.050 |
Why?
|
Hematopoiesis | 1 | 2009 | 2015 | 0.050 |
Why?
|
Risk Assessment | 3 | 2011 | 23284 | 0.050 |
Why?
|
Kidney Transplantation | 1 | 2014 | 4116 | 0.050 |
Why?
|
Bone Marrow | 2 | 2007 | 2938 | 0.050 |
Why?
|
Reoperation | 1 | 2009 | 4159 | 0.050 |
Why?
|
Cell Count | 1 | 2003 | 1920 | 0.050 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2001 | 445 | 0.040 |
Why?
|
Leukocyte Count | 2 | 2015 | 1670 | 0.040 |
Why?
|
Fibrinogen | 1 | 2001 | 914 | 0.040 |
Why?
|
Salmonella Food Poisoning | 1 | 1995 | 13 | 0.040 |
Why?
|
Frail Elderly | 1 | 2001 | 599 | 0.040 |
Why?
|
Health Status | 1 | 2009 | 4015 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2010 | 14836 | 0.030 |
Why?
|
Salmonella typhi | 1 | 1995 | 175 | 0.030 |
Why?
|
Typhoid Fever | 1 | 1995 | 163 | 0.030 |
Why?
|
Methotrexate | 1 | 2021 | 1708 | 0.030 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2017 | 671 | 0.030 |
Why?
|
Cohort Studies | 2 | 2011 | 39292 | 0.030 |
Why?
|
World Health Organization | 1 | 2019 | 1261 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2015 | 6127 | 0.030 |
Why?
|
Piperazines | 1 | 2004 | 2532 | 0.030 |
Why?
|
Emigration and Immigration | 1 | 1995 | 382 | 0.030 |
Why?
|
Cytogenetic Analysis | 1 | 2013 | 306 | 0.030 |
Why?
|
Pyrimidines | 1 | 2004 | 2950 | 0.030 |
Why?
|
Carrier State | 1 | 1995 | 541 | 0.030 |
Why?
|
Time Factors | 3 | 2008 | 41038 | 0.030 |
Why?
|
Radionuclide Imaging | 1 | 2016 | 2028 | 0.030 |
Why?
|
HLA-C Antigens | 1 | 2010 | 168 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2006 | 9488 | 0.020 |
Why?
|
International Agencies | 1 | 2010 | 229 | 0.020 |
Why?
|
Phenotype | 2 | 2018 | 16306 | 0.020 |
Why?
|
HLA-DQ Antigens | 1 | 2010 | 233 | 0.020 |
Why?
|
HLA-A Antigens | 1 | 2010 | 252 | 0.020 |
Why?
|
Neoplastic Stem Cells | 1 | 2018 | 1392 | 0.020 |
Why?
|
Aged | 6 | 2021 | 161488 | 0.020 |
Why?
|
Incidence | 2 | 2019 | 20320 | 0.020 |
Why?
|
Chimerism | 1 | 2010 | 148 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4317 | 0.020 |
Why?
|
HLA-B Antigens | 1 | 2010 | 386 | 0.020 |
Why?
|
Cell Lineage | 1 | 2018 | 2630 | 0.020 |
Why?
|
Transplantation | 1 | 2010 | 228 | 0.020 |
Why?
|
HLA-DR Antigens | 1 | 2010 | 696 | 0.020 |
Why?
|
Prospective Studies | 2 | 2010 | 50597 | 0.020 |
Why?
|
Trans-Activators | 1 | 2018 | 3053 | 0.020 |
Why?
|
Mesenchymal Stem Cells | 1 | 2018 | 1572 | 0.020 |
Why?
|
Models, Genetic | 1 | 2018 | 3539 | 0.020 |
Why?
|
Autoantibodies | 1 | 2016 | 1976 | 0.020 |
Why?
|
Animals | 4 | 2021 | 170486 | 0.020 |
Why?
|
Salvage Therapy | 1 | 2014 | 1296 | 0.020 |
Why?
|
Disease Progression | 1 | 2003 | 13298 | 0.020 |
Why?
|
Sex Factors | 1 | 2001 | 10566 | 0.020 |
Why?
|
Disease Outbreaks | 1 | 1995 | 1709 | 0.020 |
Why?
|
Blood Platelets | 1 | 2016 | 2485 | 0.020 |
Why?
|
Genome, Human | 1 | 2018 | 4493 | 0.020 |
Why?
|
Registries | 2 | 2014 | 7989 | 0.020 |
Why?
|
Pediatrics | 1 | 2019 | 3554 | 0.020 |
Why?
|
Melphalan | 1 | 2005 | 385 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2017 | 4861 | 0.020 |
Why?
|
Chemoprevention | 1 | 2006 | 313 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2010 | 936 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2013 | 4883 | 0.020 |
Why?
|
Canada | 1 | 2008 | 1915 | 0.020 |
Why?
|
Haplotypes | 1 | 2010 | 2874 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8024 | 0.020 |
Why?
|
Mutation | 2 | 2018 | 29262 | 0.010 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2006 | 903 | 0.010 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2004 | 412 | 0.010 |
Why?
|
Genetic Variation | 1 | 2018 | 6666 | 0.010 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2004 | 462 | 0.010 |
Why?
|
Genomics | 1 | 2018 | 5300 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2014 | 6765 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2015 | 3708 | 0.010 |
Why?
|
Europe | 1 | 2008 | 3104 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2018 | 20170 | 0.010 |
Why?
|
Probability | 1 | 2007 | 2474 | 0.010 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2005 | 641 | 0.010 |
Why?
|
Body Height | 1 | 2007 | 1587 | 0.010 |
Why?
|
Blood Grouping and Crossmatching | 1 | 2000 | 101 | 0.010 |
Why?
|
Liver | 1 | 2016 | 7622 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2018 | 22989 | 0.010 |
Why?
|
United States | 2 | 2022 | 67165 | 0.010 |
Why?
|
Nuclear Family | 1 | 2000 | 310 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2018 | 18375 | 0.010 |
Why?
|
Alleles | 1 | 2010 | 7090 | 0.010 |
Why?
|
Drug Evaluation | 1 | 2000 | 661 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2013 | 11126 | 0.010 |
Why?
|
Translocation, Genetic | 1 | 2004 | 1425 | 0.010 |
Why?
|
Mice | 1 | 2005 | 80876 | 0.010 |
Why?
|
Benzamides | 1 | 2004 | 1406 | 0.010 |
Why?
|
Stomatitis | 1 | 2000 | 266 | 0.010 |
Why?
|
Weight Gain | 1 | 2007 | 2193 | 0.010 |
Why?
|
El Salvador | 1 | 1995 | 41 | 0.010 |
Why?
|
Holidays | 1 | 1995 | 39 | 0.010 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2004 | 1597 | 0.010 |
Why?
|
Maryland | 1 | 1995 | 276 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2001 | 58184 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2013 | 8877 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2010 | 10803 | 0.010 |
Why?
|
Neutrophils | 1 | 2007 | 3867 | 0.010 |
Why?
|
Length of Stay | 1 | 2007 | 6257 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2014 | 17218 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2014 | 15053 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2008 | 19423 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2008 | 16008 | 0.010 |
Why?
|
Aging | 1 | 2007 | 8358 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2006 | 6991 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2000 | 11239 | 0.000 |
Why?
|
Hospitalization | 1 | 2006 | 9644 | 0.000 |
Why?
|
Population Surveillance | 1 | 1995 | 2606 | 0.000 |
Why?
|
Risk | 1 | 1995 | 9641 | 0.000 |
Why?
|